Drug Profile
Atorvastatin/sitagliptin - Merck & Co.
Alternative Names: MK-0431E; sitagliptin/atorvastatin - MerckLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics; Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrazines; Pyrroles; Small molecules; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis; Diabetes mellitus
Most Recent Events
- 19 Jun 2017 Merck terminates phase III trial in Diabetes mellitus in Germany, Bulgaria and Hungary due to business reasons (NCT01477853)
- 13 Nov 2012 Discontinued - Phase-III for Atherosclerosis in Germany (PO)
- 13 Nov 2012 Discontinued - Phase-III for Diabetes mellitus in Germany (PO)